Equillium, Inc. (NASDAQ:EQ) Short Interest Update

03 Mar 2026, 12:38 by Doug Wharley · The Cerbat Gem

Equillium, Inc. (NASDAQ:EQ – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 1,965,458 shares, a growth of 47.0% from the January 29th total of 1,336,687 shares. Based on an average trading volume of 542,633 shares, the days-to-cover ratio is presently 3.6 days. Currently, 4.6% of the company’s stock are sold short. Currently, 4.6% of the company’s stock are sold short. Based on an average trading volume of 542,633 shares, the days-to-cover ratio is presently 3.6 days.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Stifel Nicolaus started coverage on Equillium in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target for the company. Zacks Research upgraded Equillium to a “hold” rating in a research report on Thursday, February 26th. Wall Street Zen downgraded Equillium from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $3.00.

Check Out Our Latest Stock Report on EQ

Insiders Place Their Bets

In other Equillium news, COO Christine Zedelmayer sold 185,937 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $1.76, for a total transaction of $327,249.12. Following the completion of the transaction, the chief operating officer directly owned 191,444 shares of the company’s stock, valued at $336,941.44. This trade represents a 49.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 328,174 shares of company stock worth $533,163. 30.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Equillium

Several large investors have recently made changes to their positions in the company. Virtu Financial LLC raised its holdings in shares of Equillium by 133.4% during the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after buying an additional 13,591 shares during the last quarter. Millennium Management LLC bought a new position in Equillium in the 3rd quarter worth approximately $35,000. Persistent Asset Partners Ltd acquired a new stake in Equillium in the 3rd quarter valued at approximately $99,000. Royal Bank of Canada bought a new stake in Equillium during the 4th quarter valued at $124,000. Finally, Boothbay Fund Management LLC acquired a new position in Equillium during the 3rd quarter worth $174,000. Institutional investors and hedge funds own 27.05% of the company’s stock.

Equillium Stock Performance

Shares of Equillium stock traded down $0.08 during trading on Tuesday, hitting $1.84. 164,649 shares of the stock were exchanged, compared to its average volume of 485,214. Equillium has a 12 month low of $0.27 and a 12 month high of $2.35. The stock’s fifty day moving average is $1.46 and its 200 day moving average is $1.39. The stock has a market cap of $112.04 million, a PE ratio of -2.97 and a beta of 1.80.

Equillium Company Profile

(Get Free Report)

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.